



04 Jun 2018

Kathryn Nijssen  
Initiatives Manager  
Canadian Clinical Trials Coordinating Centre  
200-119 Ross Avenue,  
Ottawa, ON K1Y 0N6

Subject: Use of Model Clinical Trial Agreement

Dear Ms. Nijssen;

Our organization has reviewed the current version of the mCTA and would like to notify CCTCC and our Canadian clinical trial stakeholder community of the following:

1. We will offer and/or accept use of the mCTA for phase II and III industry sponsored clinical trials.
2. We agree to the CCTCC listing our organization as one using the mCTA and the CCTCC maintaining our contact information to facilitate ongoing mCTA initiative communications.
3. We agree to compile data on our use of the mCTA using the decided metrics and provide them to the CCTCC on an annual basis for aggregation with data from all other users and metrics reporting by CCTCC to clinical trial stakeholders.
4. We agree to suggest to the CCTCC mCTA changes (if any) on an annual basis and to participate with clinical trial stakeholders in an annual consultation about creation of subsequent mCTA versions.
5. We reserve the right at any time to notify CCTCC if we cease to use the mCTA (Current or subsequent versions) and CCTCC agrees to remove our organization from mCTA user lists.

Sincerely,

A handwritten signature in black ink, appearing to read "Doreen D'Souza", written over a horizontal line.

Doreen D'Souza

Country Head, Site Management Canada